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ABSTRACT 
The medicinal uses and applications of metals and metal complexes are of increasing clinical and commercial importance.More than 2 - 8% of 
world’s population is suffering from diabetes. The correlation of diabetes and an imbalance in metal makes metal -based therapy as an attractive 
proposition. The development of anti-diabetic metal complexes replacing insulin injection to regulate sugar levels appears to be interesting. It has 
been understood that control of the glucose level in the blood plasma has been achieved by administration of vanadium and zinc in form of 
inorganic salts. Number of vanadium and other metal complexes has been developed and all of which have shown insulin-mimetic properties. This 
paper mainly focus extensive role of metal and its complexes in biological systems and its therapeutic applications. 
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INTRODUCTION 
Diabetes mellitus (DM), a metabolic dysfunction which develops 
many secondary complications and making it the 5th leading causes 
of death of human. Globally, in 2000, the total number of people 
suffering with diabetes is estimated nearly about 171 million and is 
expected to increase 366 million by 2030 if successful strategies are 
not implemented for prevention and control [1- 3]. 
Diabetes is a condition primarily defined by the level of 
hyperglycemia giving rise to risk of microvascular damage like 
retinopathy, nephropathy and neuropathy. It is associated with 
reduced life expectancy, significant morbidity due to specific 
diabetes related microvascular complications, increased risk of 
macrovascular complications like ischemic heart disease, stroke and 
peripheral vascular disease and diminished quality of life[3]. 
Numerous factors, such as genetics, environment, eating habits, 
physiological state, hormones and stress are considered to be 
associated with the development of DM [4]. 
DM is classified as either insulin-dependent type 1 DM (caused by 
destruction of insulin producing pancreatic β cells) or noninsulin-
dependent type 2 DM (caused by aging, obesity, spiritual stress, or 
other environmental factors) which are treated by daily injections of 
insulin or several types of synthetic therapeutic substances 
respectively. Unfortunately, these methods of treatment have some 
defects. Injecting insulin several times in a day is painful and 
elevates the level of patient stress, especially in young people and 
moreover administration of synthetic therapeutic substances often 
exhibits some serious side effects [4]. 
Chronic hyperglycemia may cause alterations in the status of trace 
elements in the body and thus the essential trace elements such as 
zinc, chromium and manganese are deficient in DM. Therefore, trace 
elements may play important functions for glucose and lipid 
metabolisms, particularly insulin function in DM [5]. 
Metallotherapy is a new therapeutic strategy being used for the 
treatment of a variety of ailments viz. diabetes, rheumatoid arthritis, 
inflammatory and cardiovascular diseases as well as diagnostic 
agents. Some of the examples of the role of metal ions in biological 
systems are iron porphyrin complex of hemoglobin in red blood cells 
(RBCs) for oxygen transportation and storage, the magnesium 
porphyrin complex of chlorophyll in green plants for 
photosynthesis, and cobalt in the coenzyme B12 for the transfer of 
alkyl groups from one molecule to another molecule. The amount of 
metals present in the human body is approximately 0.03% of the 
body weight [3,7]. The following table (Table 1) illustrates the 
therapeutic activity of various metal complexes approved for clinical 
applications. 
The metal, its oxidation state, the number and types of coordinated 
ligands, and the coordination geometry of the complexes can 
provide a variety of properties. The ligands not only control the 
reactivity of the metal, but also play critical roles in determining the 
nature of interactions involved in the recognition of biological target 
sites such as DNA, enzymes and protein receptors.  
These variables provide enormous potential diversity for the design 
of metallodrugs [9].The oxidation state of the metal ion can be 
decisive in regulating the immediate in vivo response to metal-based 
pharmaceutical agents, often making the difference between a 
beneficial and a toxic response at the same administered dose of a 
metal ion, and also directing towards the metabolic pathways by 
which the compound will be integrated [10]. 
Metal based drugs to treat diabetes with metal complexes are first 
studied by Coulson and Dandona in the year 1980 and reported that 
ZnCl2 stimulate lipogenesis in rat adipocytes similarly to the action 
of insulin [1]. The idea of using metal ions for the treatment of 
diabetes originates from the report in 1899. The orally active metal 
complexes containing vanadyl (oxidovanadium(IV) ion and cysteine 
or other ligands were first proposed in 1990 [6]. Many metal 
complexes have been synthesized and evaluated to overcome the 
problems of painful insulin injection and the side effects for type 1 
or type 2 DM. So far chromium, manganese, molybdenum, copper, 
cobalt, zinc and vanadium ions have been reported to exhibit 
insulin-mimetic or enhancing insulin like properties under invitro 
and in vivo condition[7].  
Of great interest, hypoglycemiainduced bymetal compounds works 
by variety of mechanisms. Probable mechanisms of antidiabetic 
being insulin-like effects (chromium, magnesium), antioxidant effect 
(cobalt, manganese, tungstate, zinc),inhibition of enzyme 
phosphatases (vanadium), stimulation of glucose uptake, glycogen 
and lipid synthesis in muscle, adipose and hepatic tissues and 
inhibition of gluconeogenesis (chromium, cobalt) or stimulation of 
the activities of the gluconeogenic enzymes: phosphoenol pyruvate 
carboxykinase and glucose-6 phosphatase (manganese) [7,8]. Table 
2 depicts the metal and the complexes to induce hypoglycemia in 
diabetic patients [4]. 
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Table 1 Metal Complexesas Therapeutic Agents. 
Element  Compound Uses Trade names/Comments 
Approved Agents (mostly US or worldwide) 
Li  
 
Li2CO3 Manic depression Camcolit; Cibalith-S; Lithane (of many) 
Fe [Fe(NO)(CN)5]2- Vasodilation  Nipride. For acute shock. NO release 
Ga  Ga(NO3)3 Hypercalcemia of 
malignancy 
Ganite. Possible anticancer agent. In clinical 
trials for use in lymphomas 
As As2O3 Anticancer agent Trisenox. Use in acute promyelocytic leukemia 
Ag  AgNO3 Disinfectant Neonatal conjunctivitis 
 Ag(sulfadiazene) Antibacterial Flamazine; Silvadene; 1% cream is used in the treatment of burns. 
Sb SbIII(tartarate) Antiparasitic, 
leishmaniasis 
Tartar Emetic Stibophen; Astiban 
 
Pt cis-[Pt(amine)2X2] Anticancer agents Platinol; Paraplatin; Eloxatine 
Testicular, ovarian, colon cancers 
Au  Au(PEt3)(acetylthioglucose) Rheumatoid 
arthritis 
Ridaura. Orally active 
Bi Bi(sugar)polymers Antiulcer; antacid Pepto-Bismol; Ranitidine Bismutrex; De-Nol 
Hg Hg-organic 
compounds 
Antibacterial Thiomersal; mercurochrome (amongst many) 
Antifungal Slow release of Hg+2 
Agents in Clinical Trials 
Pt Polynuclear 
PtIV species 
Anticancer agents BBR3464, Satraplatin, AMD-473 





Anticancer agent NAMI-A; antiangiogenic 
V  VO(maltate)2 Type II diabetes BMOV; insulin mimetic 
Ln Ln(CO3)3 Hyperphosphatemia Fosrenol; phosphate binder 
 
Table 2: Reports of Metal Ions and the Complexes with Antidiabetic Activity in Experimental Animals and the Subjects with DM. 
Metal Ionic form Complex form 
V Vanadyl sulfate (VOSO4 ) 
 
Bis(methylcysteinato) oxovanadium(IV)  
Bis(maltolato)oxovanadium(IV) 
Sodium vanadate (NaVO3) Bis(picolinato)oxovanadium(IV) 
Cr  Bis(picolinato)chromium(III) 
Chromium polynicotinate 
Mn Manganese chloride (MnCl2)  
Co Cobalt chloride (CoCl2)   
Zn Zinc chloride (ZnCl2) Bis(picolinato)zinc(II)  
Bis(maltolato)zinc(II) 
Se  Sodium selenite (Na2SeO3)   
Mo Sodium molybdate (Na2MoO4)  
W Sodium tungstate (Na2WO4)   
 
Vanadium 
Humans usually consume 10-60 μg of vanadium through foods daily. 
The human body is estimated to contain 50-200 μg of vanadium. In 
each organ, vanadium is present at very low concentrations, 0.01-1 
μg, and is thought to play a role in a wide variety of physiological 
processes. In tissues, approximately 90% of vanadium is bound with 
proteins and 10% is present in the ionic form. The importance of 
vanadium pertaining to the growth of rats and chicks has been 
determined, but this has not been established in humans [12]. 
Vanadium complexes with organic ligands have proved to be less 
toxic, with improved solubility and lipophilicity. Designing new 
vanadium complexes requires stereochemical considerations for 
binding the complexes with receptors such as glucose transporter 
and other enzymes, as well as consideration of the redox properties 
of vanadium [9]. So far number of vanadium complexes has been 
developed; most of them have insulin-mimetic properties [13]. 
In 1985, it was discovered that a simple vanadium salt, sodium 
orthovanadate, when added to drinking water, could reverse most of 
the diabetic symptomatology of experimentally-diabetic rats, was 
exceptionally enticing [10]. It is a d-block metal which known to 
exist in a variety of oxidation states (-1, 0, +2, +3, +4 and +5) among 
which +3, +4 and +5 are accessible under physiological conditions in 
the form of V+3, vanadyl (VO2+) and vanadate (VO3-) respectively 
[11,12]. Vanadium exhibits a rich redox chemistry but in the medical 
context the oxidation states V(+4) and V(+5) appear to be of primary 
importance, both being found to participate in extra- and intra-
cellular equilibria [12].  
However, vanadyl is less toxic than the vanadate ion. Vanadyl 
complexes with maltol (3-hydroxy-2-methyl-4-pyrone) and kojic 
acid (3-hydroxy-2-hydroxymethyl-4-pyrone) which possess insulin 
mimetic activity and low toxicity profile, have been proposed for 
clinical use inhumans. Oxovanadium(IV) with maltol/ethylmaltol 
has shown enhancing insulin mimetic activity in experimental 
diabetic animals in recent years [7]. Since 1990, a wide class of 
vanadyl (oxidovanadium(IV) complexes involving 
bis(methylcysteinato) [VO(cysm)2]- (1990), bis(L-tartrato) 
[(V2O4)(L-tart)2]- (1990), bis(maltolato) [VO(ma)2]- (1992), 
bis(pyrrolidine-N-dithiocarbamato) [VO(pdc)2]- (1994), 
bis(picolinato) [VO(pa)2]- (1995), and bis(1-oxy-2-pyridinethiolato) 
[VO(opt)2]- (1999) have been found to improve the hyperglycemic 
state in streptozotocin induced diabetes in rats (STZ-rats). In 
particular, studies on VO(pa)2 with a VO(N2O2) coordination 
environment and bis(3-hydroxy-4-pyronato) [VO(3hp)2]-, bis(1,4-
dihydro-2-methyl-4-oxo-3-pyridinolato)- and bis(1,2-dihydro-2-
oxo-1 pyrimidinolato) oxidovanadium (IV) complexes with a VO(O4) 
coordination environment have been intensively performed to find 
more potent analogues than the parent complexes, leading to the 
discovery of the linear relationship between in vitro insulin-mimetic 
activity and the partition coefficient of these complexes [6]. 
Arumugam et al. 
Int J Pharm Pharm Sci, Vol 6, Issue 7, 40-44 
42 
 
The discovery that modification of the vanadium core by chelation 
could improve biodistribution and tolerability was found to be a 
crucial step in development of vanadium compounds for treatment 
of diabetes. Bis(maltolato) oxovanadium(IV) or BMOV is the first 
vanadium complexes shown superior activity over other inorganic 
vanadium sources (e.g. VOSO4 or NaVO3) both in vivo and/or in vitro 
studies [7,10] (Fig 1). 
 
Fig. 1: Bis(maltolato)oxovanadium(IV), BMOV, the First Purpose 
Designed Vanadium-Based Insulin Enhancing Pharmaceutical 
Agent 
 
Earlier reports haveshown that VV-dipicolinato complex has more 
insulin enhancing effect compared to BMOV. New orally active β-
diketonato complexes such as VO(acac)2 and bis(α-
furancarboxylato) oxovanadium(IV) have shown glucose lowering 
ability comparable to BMOV and possess high water solubility and 
less toxicity when orally administered in diabetic rats. Vanadium 
complex, bis(pyridine-2-carboxylato) oxovanadium(IV) [VO(pic)2] 
has shown higher insulin-mimetic activity than VOSO4 [7]. 
Recently, the first human Phase I clinical trial was carried out by 
Medeval Ltd. in Manchester, UK, was to assess the safety and 
tolerability of vanadium-based antidiabeticprodrug, 
bis(ethylmaltolato) oxovanadium(IV) (BEOV), the ethylmaltol 
analogue of BMOV. The overall objectives of this study were to 
assess the health effects of single, escalating doses of orally 
administered BEOV; determination of the pharmacokinetics 
parameters of BEOV from measured plasma, urinary, fecal and total 
biological fluids[V] and compare the bioavailability of a well-
tolerated dose of oral BEOV and an equivalent molar dose of oral in 
bothfasted and fed state. The outcome of this initial clinical trial 
suggested that no observed adverse health effectsin any of the 
human volunteers including non-diabetic, gastrointestinal 
disturbances, liver and kidney function and blood parameters all 
remained within normal levels throughout the study. 
Pharmacokinetic analysis showed a clear, non-proportional, dose-
dependence in vanadium uptake from BEOV, along with a more 
rapid and efficient uptake compared to that from VOSO4.Fasted 
subjects absorbed more vanadium from BEOV than did fed subjects. 
Lastly, the relative bioavailability of vanadium from BEOV was 
estimated to be three times that of an equivalent dose of vanadium 
from VOSO4, corroborating earlier results in experimental animals 
[10] (Fig 2). 
 
Fig. 2: Bis(ethylmaltolato) Oxovanadium (IV), BEOV, 
VanadiumBased AntidiabeticProdrug 
 
In addition to the therapeutic effect of vanadium ion (Va+)and 
vanadium complexes, these vanadium compounds have a preventive 
effect on the onset of streptozocin STZ-induced diabetes in terms of 
nitric oxide released from the macrophages [11]. 
Zinc 
Zinc is a natural component of insulin, a substance crucial to the 
regulation of sugar metabolism in all living and plays a major role in 
hundreds of zinc enzymes and in thousands of protein domains. In 
addition to vanadium complexes, zinc complexes have been 
proposed to be the new candidates in treating type 2 DM. In fact, 
zinc and diabetes interact at several points during metabolism in a 
cell. Zinc seems to have a similar action to insulin, in stimulating 
uptake of glucose by adipose tissue. A deficiency of zinc results in 
reduced uptake of glucose by adipose tissue. Of interest is the fact 
that the zinc content of secretory vesicles is, at best, barely adequate 
to complex stored insulin as the 2-zinc insulin hexamer. 
Surprisingly, zinc was found to have important physiological and 
pharmacological functions involving an insulin-mimetic activity. 
Hyperzincuria and impaired intestinal absorption of zinc results in 
diabetes. Higher zinc intake has also been associated with a slightly 
lower risk of type 2 diabetes in women [13]. More clinical data 
would be needed to prove zinc has an insulin-mimetic effect and 
protects against oxidative damage associated with the disease for 
the treatment of diabetes mellitus with an increased risk of zinc 
deficiency [14].  
Upon oral administration of Zinc(II) complexes containing bis(6-
methylpicolinato) [Zn(6mpa)2], bis(maltolato) [Zn(ma)2], bis(1-oxy-
2-pyridonato) [Zn(opd)2]-, and bis(1-oxy-2-pyridinethiolato) 
[Zn(opt)2],it has found to exhibit anti-diabetic activity and 
ameliorate hyperinsulinemia and massive hereditary obesity in 
experimental studies on mice. In addition, structure–activity 
relationships on zinc complexes with dithiocarbamates and 
pyridine-2-sulfonates made to create new potential zinc complexes 
such as bis(pyrrolidine-N-dithiocarbamato) Zn [Zn(pdc)2] and bis(3-
methylpyridine-2-sulfonato)Zn, respectively under invitro insulin 
mimetic activity. Oral administration of Zn(3hp)2-related complexes 
with a Zn(O4) coordination environment helped to induce high 
quality anti-diabetic properties and also a few complexes exhibited 
not only anti-diabetic activity but also anti-metabolic syndrome 
activity in respect to hypoglycemic effect and adiponectin secretion 
enhancing effect, when it was given to STZ-rats by daily 
intraperitoneal injections[7].There is evidence that zinc is utilized in 
the beta cells of the pancreas to both store and release insulin as 
required. Release of insulin from the beta cells is accompanied by a 
loss of zinc. Sosupplementation ofzinc may produce a significant 
improvement in glucose level.  
Copper 
Copper (Cu) is an essential transition metals that is required for a 
variety of molecules to maintain their normal structures and 
functions and for cells to live, grow and proliferate. Copper is found 
in the liver, gallbladder, lungs and heart and is needed for synthesis 
of hemoglobin, proper iron metabolism and maintenance of blood 
vessels [15]. Copper seems to play a crucial role especially in 
electron transfer reactions[2]. Copper insufficiency results in several 
abnormalities of the immune system, abnormal metabolism of 
glucose and cholesterol, more oxidative damage [17]. Copper 
complexes have different pharmacological actions such as antiulcer, 
anticonvulsant, anticancer, and antidiabetic activity[16]. Yasumatsu 
et al.[18] reported that by single intraperitoneal injection copper 
(II)-picolinate [Cu (Pic) 2] complexes have shown a higher 
hypoglycemic effect in animal models.  
Copper (Cu(II)) chelator that prevents or reverses diabetic copper 
overload, thereby suppressing oxidative stress. Treatment with 
copper chelating agent like tetrathiomolybdatereduces both serum 
copper ion and ROS levels and consequently rises glucose and lipid 
metabolism in diabetic mice [19]. Copper sulfate treatment in 
diabetes showed beneficial effects with preservation of β-cell 
function by reducing free radicals or through reduction in glucose 
levels [20]. 
Chromium 
Chromium is an essential element required for normal carbohydrate 
and lipid metabolism. The two most common forms of chromium are 
trivalent chromium (III) and hexavalent chromium (VI). Chromium 
(III) is the principal form in foods as well as the form utilized by the 
body. Chromium, Cr (III) the most stable oxidation state, is 
considered as an essential micronutrient for humans by many 
nutritionists. In 1950s, Schwarz and Mertz conducted experiments 
on nutrient-deficient rats and suggested that a biological Cr (III) 
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compound could act as a nutritional enhancement particularly 
essential for glucose metabolism. The Cr (III) complexes had better 
bioavailability and more beneficial influences on the improvement 
of controlling blood glucose and proposed to act as safer 
antidiabetics [2]. Supplementation of chromium significantly 
improves glucose level among patients with diabetes but fails to 
show any significant effect on glucose metabolism in healthy 
volunteers [21]. Treatment with Chromium picolinate (CrPic) 
improves glycemic control in diabetic patients [22]. Chromium 
picolinate is more bioavailable than other supplemental forms of 
chromium and therefore may be more efficacious. 
Cobalt  
Cobalt is one of the most important trace elements in the world of 
animals and humans and finds therapeutic application in 
pharmacological fields. In the form of vitamin B12 (cobalamin), this 
metal plays a number of crucial roles in many biological functions. 
Vitamin B12 is the only metal-containing water-soluble vitamin that 
is stored in the liver and must come from the diet. Cobalamin is 
necessary for DNA synthesis, formation of red blood cells and 
maintenance of the nervous system, growth and development of 
children. Cobalt is used to treat anaemia with pregnant women, 
because it stimulates the production of red blood cells.Cobalt was 
found to boost the effects of insulin and its action. Treartment with 
cobalt chloride (CoCl2) decreases the glycemia of diabetic rats which 
may be mediated by gene expression of GLUT-1 mRNA. Treatment 
with cobalt chloride showed significant decline in blood glucose in 
STZ induced diabetic rats but no observed change in plasma/serum 
insulin levels of normal or diabetic rats. Cobalt is the most important 
contributor to metal ion toxicityin patients both in single and pure 
form. Different forms of cobalt complexes have been reported to 
reduce the potential toxicity of cobalt without modifying its 
therapeutic effect[2]. The glycemic lowering effect of glucosaminic 
acid-cobalt chelate has been reported to be effectiveagent for 
diabetes [23]. Cobalt therapy may prove effective in improving the 
impaired antioxidant status during the early state of diabetes and 
ascorbic acid supplementation at this dose potentiates the 
effectiveness of cobalt action [24,25]. 
Tungsten  
Tungstate counteracts diabetes in the form of sodium tungstate. 
Studies in several animal models of diabetes have shown sodium 
tungstate to be an effective anti-diabetic agent and found to be less 
toxic both in diabetic and healthy animals [26, 27]. Administration of 
this metal enhances the insulin activity rather than increased insulin 
levels [28] and also treatment with this metal found to rise extra-
islet β-cell replication without modifying intra islet β-cell replication 
rates [29]. Tungstate improves pancreatic function through a 
combination of hyperglycemia-independent pathways and through 
its own direct and indirect effects, whereas the MAPK pathway has a 
key role in the tungstate-induced increase of beta cell proliferation 
[30]. 
Manganese  
Manganese (Mn) plays a key role in a number of physiologic 
processes and is considered tobe essential for the carbohydrate, 
amino acid and cholesterol metabolism. The human body does not 
require much of this element, but several biological uses of 
manganese are critical to the proper functioning of the body, and it 
is often included in small doses in mineral supplements. Manganese 
seems to be particularly important for the proper functioning of 
enzymes. These enzymes have a variety of different functions. Some 
aid in repairing damage to the body. Others are antioxidants. 
Additional enzymes make use of manganese to aid in the 
development of strong and healthy bones. It is considered to be a 
key component of metalloenzymes such as Se–Cyscontaining 
glutathione peroxidase, Cu/Fe cytochrome C oxidase or different 
types of superoxide dismutase, which are in turn important for 
intra- and extra-cellular antioxidant defense mechanism[2]. 
Synthetic derivative of manganese found to be used as potent 
therapeutic agent in diabetes. Two newly classified antioxidants 
namely EUK-8 and EUK-134 reported to reduce the serum levels of 
glucose [31]. 
Molybdenum  
Molybdenum (Mo), an important trace element plays a major role 
for participation in the active sites of metalloenzymes. Molybdenum 
is capable of forming complexes with many compounds of biological 
importance: carbohydrates, amino acids, flavins, porphyrins; but is 
probably taken up, transported, and excreted in animals as the 
simple molybdate ion, [MoO4]2-. Molybdenum is essential for life and 
is much less toxic than many other metals of industrial importance. 
Most organisms including human beings require molybdenum for 
their existence. Molybdenum alongwith tungstate helps in the key 
transformations in the metabolism of nitrogen, sulphur, carbon, 
arsenic, selenium and chlorine compounds. This element plays a 
crucialrole in the structure of certain enzymes involving redox 
reactions [32]. Molybdenum in different forms have shown to 
possess insulin mimetic properties and hence it used in the 
treatment of diabetes. Sodium molybdate (Na2MoO4) and its 
complex compounds such as cis-MoO2L2 (L ¼ maltol (3-hydroxy-2-
methyl-4 pyrone)) were found to reduce the levels of blood glucose 
significantly and also free fatty acids [33]. Combination of 
molybdenum and ascorbic acid exhibited significant insulin-like 
activites and also shown cardio protective effects [34].  
Tin  
Tin generates a wide variety of biological activities deriving from its 
chemical character. Tin is an ultra-trace element in humans. It has 
been suggested that the amount of tin found in a healthy diet should 
be the value used to describe appropriate intake. Vangabhasma, an 
Ayurvedic preparation of tin is used tradionally for treatment of 
diabetes. Vangabhasma is purified and calcinated form of tin with 
additional herbs[35]. 
Siddha System Of Medicine 
Siddha system of medicine, one of the ancient medical systems has 
the great potential of treating many disease ailments. Siddha system 
of Medicine, many single and poyherbal formulations and higher 
medicines like Parpam, Chendooramand Chunnamhave been 
practiced to cure or control diabetes mellitus from time immemorial. 
The familiar Siddha medicines prescribed for diabetes are 
AvaraiKudineer (decoction), MadhumegaChooranam(Fine powder), 
ThetranChooranam, SeenthilChooranam, NaavalChooranam, 
AbragaParpam,Vangaparpam etc. In Siddha, the management of a 
disease not only depends on the medicine but the modification of 
food, habits, and lifestyle also. In addition to this, yoga and exercise 
therapy also plays a key role for themanagement of 
diabetes.SidhhaKudineer, a polyherbal formulations equally referred 
to Khashayasin Ayurveda are more useful to prevent the diabetes 
and their associated complications.  
Oral administration of Siddha formulation (Madhumegachuranam) 
ameliorated the plasma glucose and lipid levels in alloxan- induced 
diabetic rats reported by Vadivelanet al.Anbu et al. studied 
thatAavaraiyathichurnamis one of the herbal based Siddha anti 
diabetic formulation for Type II maturity onset diabetes mellitus 
possess significant hypoglycemic effect when compared with non-
treated diabetic rats. KovaiKizhanguChooranam found to possess 
remarkable anti-diabetic action in alloxan induced diabetic rats was 
reported by Parthiban et al. [36-40]. 
CONCLUSION 
Metal complexes offer a platform for the design of novel therapeutic 
compounds. The metal compounds offer new properties that cannot 
be found amongst purely organic agents. Treatment of diabetes 
mellitus with metal complexes is a new therapeutic strategy. Although 
various metals like chromium, manganese, molybdenum, tungsten, 
copper, cobalt, zinc andvanadium were reported to exhibit insulin 
mimetic activity out of these a wide class of vanadium, copper and zinc 
complexes was found to be effective for treating diabetes in 
experimental animals. Since metallotherapy overcome the problems of 
painful insulin injection and side effects for type 1 or type 2 DM; the 
encouraging results of preclinical and clinical studies with metal 
compounds form the basis for further investigations towards the 
development of metallodrugs for better healthcare. 
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